Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

被引：0

作者：

Fontana, A. ^{[1
]}

Galli, L. ^{[2
]}

Derosa, L. ^{[2
]}

Minuti, G. ^{[2
]}

D'Arcangelo, M. ^{[2
]}

Bursi, S. ^{[2
]}

Landi, L. ^{[2
]}

Bocci, G. ^{[3
]}

Santini, D. ^{[4
]}

Falcone, A. ^{[3
]}

机构：

[1] Azienda Osped Univ Pisana, Pisa, Italy

[2] ASL6 Livorno, Med Oncol, Livorno, Italy

[3] Univ Pisa, Pisa, Italy

[4] Univ Campus Biomed, Rome, Italy

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)71414-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：417 / 417

页数：1

共 50 条

[21] A PHASE I STUDY OF ORAL PANOBINOSTAT (LBH589) ALONE AND IN COMBINATION WITH DOCETAXEL (DOC) AND PREDNISONE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) [J].

Rathkopf, D. E. ;

Wong, B. Y. ;

Ross, R. W. ;

George, D. J. ;

Picus, J. ;

Atadja, P. ;

Yang, W. ;

Culver, K. W. ;

Woo, M. M. ;

Scher, H. I. .

ANNALS OF ONCOLOGY, 2008, 19 :199-200

[22] A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC) [J].

Rathkopf, D. E. ;

Wong, B. Y. ;

Ross, R. W. ;

George, D. J. ;

Picus, J. ;

Tanaka, E. ;

Chen, Y. ;

Atadja, P. ;

Yang, W. ;

Culver, K. W. ;

Scher, H. I. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[23] A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC) [J].

Sonpavde, G. ;

Matveev, V. B. ;

Burke, J. M. ;

Caton, J. R. ;

Fleming, M. T. ;

Karlov, P. A. ;

Holmlund, J. ;

Wood, B. A. ;

Brookes, M. ;

Leopold, L. H. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[24] A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC) [J].

Sonpavde, G. ;

Matveev, V. B. ;

Burke, J. M. ;

Caton, J. R. ;

Fleming, M. T. ;

Karlov, P. A. ;

Holmlund, J. ;

Wood, B. A. ;

Brookes, M. ;

Leopold, L. H. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)

[25] Docetaxel and curcuminoids combination in patients with castration-resistant prostate cancer: A phase II study [J].

Mahammedi, H. ;

Pouget, M. ;

Planchat, E. ;

Cure, H. ;

Durando, X. ;

Van-Praagh, I. ;

Savareux, L. ;

Abrial, C. ;

Chollet, P. ;

Eymard, J. C. .

EUROPEAN JOURNAL OF CANCER, 2013, 49 :S696-S696

[26] A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C plus DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC). [J].

Al Harthy, Munjid ;

Madan, Ravi Amrit ;

Karzai, Fatima ;

Petrylak, Daniel Peter ;

Kim, Joseph W. ;

Arlen, Philip M. ;

Theoret, Marc Robert ;

Marte, Jenn ;

Bilusic, Marijo ;

Couvillon, Anna ;

Chun, Guinevere ;

Owens, Helen ;

Hankin, Amy ;

Cordes, Lisa M. ;

Figg, William Douglas ;

Gulley, James L. ;

Dahut, William L. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)

[27] Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial [J].

Caffo, Orazio ;

Ortega, Cinzia ;

Nole, Franco ;

Gasparro, Donatello ;

Mucciarini, Claudia ;

Aieta, Michele ;

Zagonel, Vittorina ;

Iacovelli, Roberto ;

De Giorgi, Ugo ;

Facchini, Gaetano ;

Veccia, Antonello ;

Palesandro, Erica ;

Verri, Elena ;

Buti, Sebastiano ;

Razzini, Giorgia ;

Bozza, Giovanni ;

Maruzzo, Marco ;

Ciccarese, Chiara ;

Schepisi, Giuseppe ;

Rossetti, Sabrina ;

Maines, Francesca ;

Kinspergher, Stefania ;

Fratino, Lucia ;

Ermacora, Paola ;

Nicodemo, Maurizio ;

Giordano, Monica ;

Sartori, Donata ;

Scapoli, Daniela ;

Sabbatini, Roberto ;

Lo Re, Giovanni ;

Morelli, Franco ;

D'Angelo, Alessandro ;

Vittimberga, Isabella ;

Lippe, Paolo ;

Carrozza, Francesco ;

Messina, Caterina ;

Galli, Luca ;

Valcamonico, Francesca ;

Porta, Camillo ;

Pappagallo, Giovanni ;

Aglietta, Massimo .

EUROPEAN JOURNAL OF CANCER, 2021, 155 :56-63

[28] A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer [J].

Porsch, Markus ;

Ulrich, Matthias ;

Wendler, Johann Jakob ;

Liehr, Uwe-Bernd ;

Reiher, Frank ;

Janitzky, Andreas ;

Baumunk, Daniel ;

Schindele, Daniel ;

Seseke, Florian ;

Lux, Anke ;

Schostak, Martin .

CHEMOTHERAPY, 2014, 60 (02) :129-134

[29] Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results [J].

Fontana, A. ;

Bocci, G. ;

Galli, L. ;

Fontana, E. ;

Galli, C. ;

Landi, L. ;

Fioravanti, A. ;

Di Marsico, R. ;

Del Tacca, M. ;

Facone, A. .

EJC SUPPLEMENTS, 2007, 5 (04) :288-288

[30] Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): Preliminary clinical and pharmacodynamic results [J].

Fontana, A. ;

Bocci, G. ;

D'Arcangelo, M. ;

Galli, L. ;

Fontana, E. ;

Galli, C. ;

Landi, L. ;

Fioravanti, A. ;

Orlandi, P. ;

Barletta, M. ;

Marsico, R. ;

Barsanti, G. ;

Andreuccetti, M. ;

Del, Tacca M. ;

Falcone, A. .

ANNALS OF ONCOLOGY, 2007, 18 :82-82

← 1 2 3 4 5 →